In the first quarter of fiscal year 2026, Medtronic saw growth in its overall revenue and neuroscience portfolio, according to financial results posted Aug. 19.
Five things to know:
1. Total revenue reached $8.6 billion, an increase of 8.4% year over year.
2. Medtronic’s neuroscience portfolio saw quarterly gains of 4.3% with $2.4 billion.
3. The cranial and spinal technologies segment within neuroscience saw a 5.5% increase year over year with $1.2 billion. Neuromodulation sales grew 10.2%, and specialty therapies revenue decreased 1.5%.
4. Medtronic’s U.S. sales increased 3.5% year over year with $4.2 billion. Global sales were $4.4 billion, a 6.1% increase.
5. The company saw net income of $1 billion and expects fiscal year 2026 revenue to grow 6.5% to 6.8% compared to fiscal year 2025.
